Shiraz University of Medical Sciences
Shiraz, Fars, Iran
NCT Number: NCT01147354
The aim of this study is to evaluate the effect of selenium supplementation on oxidative, inflammatory and nutritional markers in hemodialysis patients.
Looking for future studies?
Notify Me18 year–80 year
All sexes
Interventional
Phase 3
Shiraz, Fars, Iran
After screening all of 280 patients under regular HD in Faghihi Hospital Hemodialysis Center, 80 stable patients in the age range of 18-80 years old were found to be eligible for enrollment and gave their informed consent to participate in this trial. Subjects were excluded if they were prescribed any multivitamins or immunosuppressive drugs or taking antioxidant supplements including vitamin E, vitamin C, lipoic acid, omega-3 fatty acids, soy extracts and green-tea preparations within 2 months prior to enrollment in the study or if they had been hospitalized in the previous month, we also excluded the ones who were pregnant or had active infections. The Ethics Committee of Shiraz University of Medical Sciences reviewed and approved the protocol of this study.These patients were randomly assigned in a 1:1 ratio into 2 groups of selenium(200µg) or placebo and were followed for 12 weeks.In order to determine the nutritional statuses of all patients, at the baseline, the questions of SGA and MIS questionnaire were read to the patients and completed in person by the main investigator. The questions of SGA and MIS were also asked by the same person at the end of treatment phase.Before the onset of the treatment and after the end of the treatment phase of the study, 10cc blood samples were taken from each patient.The blood was taken from the patient's arm used for hemodialysis cannula just before the beginning of the hemodialysis procedure. The serum was separated by centrifugation at 3000 g/min for 5 min and stored at -70°C. Serum levels of malondialdehyde (MDA), interleukin-6 (IL-6), high sensitive C-reactive protein (HSCRP), ferritin, transferrin, homocysteine, calcium , phosphate, parathyroid hormone (PTH), albumin, blood urea nitrogen (BUN), and creatinine as well as hemoglobin (Hb) levels were measured in all patients at the baseline and at the end of treatment phase of study.The aim of this study was to evaluate the effect of selenium supplementation on oxidative, inflammatory and nutritional markers in hemodialysis patients.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The patients in this arm took 200 micrograms of selenium yeast daily for 12 weeks.
The patients in this arm took one placebo capsule daily for 12 weeks.
Time frame: 12-weeks
changes in nutritional status according to SGA from baseline to end of treatment
Time frame: 12-weeks
Time frame: 12-weeks
Time frame: 12-weeks
Time frame: 12-weeks
Time frame: 12-weeks
Time frame: 12-weeks
Time frame: 12-weeks
Time frame: 12-weeks
Time frame: 12-weeks
Time frame: 12-weeks
Time frame: 12-weeks
Time frame: 12-weeks
Time frame: 12-weeks
Time frame: 12-weeks
Zahra Sohrabi
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06092515
Conjunctival Diseases, Conjunctivitis
Karachi, Sindh, Pakistan
View Trial DetailsNCT04965948
Dyslipidemias, Glucose Metabolism Disorders
Pavia, Lombardy, Italy
View Trial DetailsNCT02232113
Anemia, Disease
Taipei, Taiwan
View Trial DetailsNCT01874106
Diet Therapy, Inflammation
Shiraz, Fars, Iran
View Trial Details